【佳学基因靶向药物基因检测】EGFR‑VEGF 的双重抑制：治疗具有 EGFR 突变的晚期非小细胞肺癌的有效方法（综述）

基因检测费用热点

与同行交流时肿瘤检测的时间和空间对治疗效果的影响知道《Int J Oncol》在 2023 Feb;62(2):26.发表了一篇题目为《Review》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Qian Wang, Anqi Zeng, Min Zhu, Linjiang Song等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤基因检测及靶向药物治疗研究关键词：

表皮生长因子受体,血管内皮生长因子,联合治疗,双重抑制,非小细胞肺癌,靶向治疗。

肿瘤治疗检测基因临床应用结果

在全球范围内，肺癌的发病率和死亡率逐年上升。许多不良习惯和环境因素与肺癌有关，包括吸烟、接触二手烟、职业接触、呼吸系统疾病和遗传。目前，低剂量螺旋CT常规是肺癌诊断的首选。然而，病理检查仍然是诊断肺癌的金标准。根据癌症的分类和分期，可选择手术、放疗、化疗、靶向治疗和免疫治疗等治疗方案。 EGFR通路的激活可以促进肿瘤细胞的存活和增殖，VEGF通路可以促进血管的形成，从而促进肿瘤的生长。在具有 EGFR 突变的非小细胞肺癌 (NSCLC) 中，EGFR 激活可以通过缺氧非依赖性机制促进 VEGF 上调，从而促进肿瘤生长。 VEGF的上调可以使肿瘤细胞对EGFR抑制剂产生耐药性。此外，VEGF信号的表达还受到其他因素的影响。因此，使用单一的EGFR抑制剂并不能完全抑制VEGF信号的表达。为了克服这个问题，VEGF抑制剂和EGFR抑制剂联合应用成为了首选方法。双重抑制不仅可以克服肿瘤细胞对EGFR抑制剂的耐药性，还可以显着延长NSCLC患者的无进展生存期。本综述讨论了 EGFR 和 VEGF 通路之间的关联，以及 EGFR-VEGF 通路双重抑制的特征。血管内皮生长因子；联合治疗；双重抑制；非小细胞肺癌；靶向治疗。

肿瘤发生与革命国际数据库描述：

On a global scale, the incidence and mortality rates of lung cancer are gradually increasing year by year. A number of bad habits and environmental factors are associated with lung cancer, including smoking, second‑hand smoke exposure, occupational exposure, respiratory diseases and genetics. At present, low‑dose spiral computed tomography is routinely the first choice in the diagnosis of lung cancer. However, pathological examination is still the gold standard for the diagnosis of lung cancer. Based on the classification and stage of the cancer, treatment options such as surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy are available. The activation of the EGFR pathway can promote the survival and proliferation of tumor cells, and the VEGF pathway can promote the formation of blood vessels, thereby promoting tumor growth. In non‑small cell lung cancer (NSCLC) with EGFR mutation, EGFR activation can promote tumor growth by promoting VEGF upregulation through a hypoxia‑independent mechanism. The upregulation of VEGF can make tumor cells resistant to EGFR inhibitors. In addition, the expression of the VEGF signal is also affected by other factors. Therefore, the use of a single EGFR inhibitor cannot completely inhibit the expression of the VEGF signal. In order to overcome this problem, the combination of VEGF inhibitors and EGFR inhibitors has become the method of choice. Dual inhibition can not only overcome the resistance of tumor cells to EGFR inhibitors, but also significantly increase the progression‑free survival time of patients with NSCLC. The present review discusses the associations between the EGFR and VEGF pathways, and the characteristics of dual inhibition of the EGFR‑VEGF pathway.Keywords: EGFR; VEGF; combination therapy; dual inhibition; non‑small cell lung cancer; targeted therapy.